Evidence map›Paper›PMID 42864409›Full record

ArticleNature chemical biology2026

PUS7 pseudouridylation of 7SK orchestrates human somatic cell reprogramming into iPS cells.

Hongxia Cai, Cheng-Wei Ju, Jianfei Chao, Yunzheng Liu, Peng Ye, Xuanhao Zhu, Ruitu Lyu, Yutao Zhao, Chenyou Zhu, Yuxuan Li and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hongxia Cai *Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-1063-7756
Cheng-Wei Ju *Department of Chemistry, The University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-2250-8548
Jianfei ChaoDepartment of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Yunzheng LiuDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0009-0003-0559-7440
Peng YeDepartment of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Xuanhao ZhuDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0009-0004-4055-8743
Ruitu LyuDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.
Yutao ZhaoDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.
Chenyou ZhuDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.
Yuxuan LiDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Xiwei WuThe Integrative Genomics Core, City of Hope Medical Center, Duarte, CA, USA.
Arthur LiThe Integrative Genomics Core, City of Hope Medical Center, Duarte, CA, USA.
Jiangbo WeiDepartment of Chemistry and Department of Biological Sciences, National University of Singapore, Singapore, Singapore.ORCID http://orcid.org/0000-0003-2691-6490
Li-Sheng ZhangDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-1872-9978
Fowzan Sami AlkurayaDepartment of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.ORCID http://orcid.org/0000-0003-4158-341X
Arjan P M de BrouwerDepartment of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
Chuan HeDepartment of Chemistry, The University of Chicago, Chicago, IL, USA. chuanhe@uchicago.edu.ORCID http://orcid.org/0000-0003-4319-7424
Yanhong ShiDepartment of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, Duarte, CA, USA. yshi@coh.org.ORCID http://orcid.org/0000-0002-3938-5839

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reprogramming human somatic cells into induced pluripotent stem cells (iPS cells) provides huge potential for regenerative medicine but its molecular regulation remains incompletely understood. In this study, we identify PUS7 as an RNA modification checkpoint that promotes acquisition of pluripotency. PUS7 loss markedly impairs reprogramming, whereas its overexpression accelerates reprogramming efficiency and kinetics. Mechanistically, PUS7 pseudouridylates U250 of the chromatin-associated noncoding RNA 7SK, enhancing its interaction with the BRG/BRM-associated factor (BAF) complex. Loss of this modification disrupts 7SK-BAF association, reduces BAF chromatin occupancy and decreases global chromatin accessibility. We further establish PSKM (PUS7, SOX2, KLF4, MYC) reprogramming, which generates iPS cells with faithful imprinting, robust lineage potential and improved developmental fidelity. PSKM-iPS cells differentiate efficiently toward neural and hematopoietic lineages and undergo gastrulation-like morphogenesis. These findings link 7SK pseudouridylation to chromatin remodeling and establish PSKM as a framework for generating high-quality human iPS cells for modeling and regenerative medicine.

Identifiers

PMID42864409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.